Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 29 entries
Sorted by: Best Match Show Resources per page
DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies.

Bioinformatics (Oxford, England)

Fu C, Jin G, Gao J, Zhu R, Ballesteros-Villagrana E, Wong ST.
PMID: 23681121
Bioinformatics. 2013 Jul 15;29(14):1834-6. doi: 10.1093/bioinformatics/btt279. Epub 2013 May 15.

SUMMARY: Systematic studies of drug repositioning require the integration of multi-level drug data, including basic chemical information (such as SMILES), drug targets, target-related signaling pathways, clinical trial information and Food and Drug Administration (FDA)-approval information, to predict new potential...

Cite
Fu C, Jin G, Gao J, et al. DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies. Bioinformatics. 2013;29(14):1834-6doi: 10.1093/bioinformatics/btt279.
Fu, C., Jin, G., Gao, J., Zhu, R., Ballesteros-Villagrana, E., & Wong, S. T. (2013). DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies. Bioinformatics (Oxford, England), 29(14), 1834-6. https://doi.org/10.1093/bioinformatics/btt279
Fu, Changhe, et al. "DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies." Bioinformatics (Oxford, England) vol. 29,14 (2013): 1834-6. doi: https://doi.org/10.1093/bioinformatics/btt279
Fu C, Jin G, Gao J, Zhu R, Ballesteros-Villagrana E, Wong ST. DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies. Bioinformatics. 2013 Jul 15;29(14):1834-6. doi: 10.1093/bioinformatics/btt279. Epub 2013 May 15. PMID: 23681121; PMCID: PMC3702253.
Copy Download .nbib Format: NLM
Drug repurposing from the perspective of pharmaceutical companies.

British journal of pharmacology

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D.
PMID: 28369768
Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18.

Drug repurposing holds the potential to bring medications with known safety profiles to new patient populations. Numerous examples exist for the identification of new indications for existing molecules, most stemming from serendipitous findings or focused recent efforts specifically limited...

Cite
Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2017;175(2):168-180doi: 10.1111/bph.13798.
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., Papapetropoulos, S., Grossman, I., & Laifenfeld, D. (2018). Drug repurposing from the perspective of pharmaceutical companies. British journal of pharmacology, 175(2), 168-180. https://doi.org/10.1111/bph.13798
Cha, Y, et al. "Drug repurposing from the perspective of pharmaceutical companies." British journal of pharmacology vol. 175,2 (2018): 168-180. doi: https://doi.org/10.1111/bph.13798
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. PMID: 28369768; PMCID: PMC5758385.
Copy Download .nbib Format: NLM
A miRNA-driven inference model to construct potential drug-disease associations for drug repositioning.

BioMed research international

Chen H, Zhang Z.
PMID: 25789319
Biomed Res Int. 2015;2015:406463. doi: 10.1155/2015/406463. Epub 2015 Feb 19.

Increasing evidence discovered that the inappropriate expression of microRNAs (miRNAs) will lead to many kinds of complex diseases and drugs can regulate the expression level of miRNAs. Therefore human diseases may be treated by targeting some specific miRNAs with...

Cite
Chen H, Zhang Z. A miRNA-driven inference model to construct potential drug-disease associations for drug repositioning. Biomed Res Int. 2015;2015:406463doi: 10.1155/2015/406463.
Chen, H., & Zhang, Z. (2015). A miRNA-driven inference model to construct potential drug-disease associations for drug repositioning. BioMed research international, 2015406463. https://doi.org/10.1155/2015/406463
Chen, Hailin, and Zhang, Zuping. "A miRNA-driven inference model to construct potential drug-disease associations for drug repositioning." BioMed research international vol. 2015 (2015): 406463. doi: https://doi.org/10.1155/2015/406463
Chen H, Zhang Z. A miRNA-driven inference model to construct potential drug-disease associations for drug repositioning. Biomed Res Int. 2015;2015:406463. doi: 10.1155/2015/406463. Epub 2015 Feb 19. PMID: 25789319; PMCID: PMC4350970.
Copy Download .nbib Format: NLM
Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis.

Bioinformatics (Oxford, England)

Carrella D, Napolitano F, Rispoli R, Miglietta M, Carissimo A, Cutillo L, Sirci F, Gregoretti F, Di Bernardo D.
PMID: 24558125
Bioinformatics. 2014 Jun 15;30(12):1787-8. doi: 10.1093/bioinformatics/btu058. Epub 2014 Feb 20.

SUMMARY: Elucidation of molecular targets of a compound [mode of action (MoA)] and its off-targets is a crucial step in drug development. We developed an online collaborative resource (MANTRA 2.0) that supports this process by exploiting similarities between drug-induced...

Cite
Carrella D, Napolitano F, Rispoli R, et al. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis. Bioinformatics. 2014;30(12):1787-8doi: 10.1093/bioinformatics/btu058.
Carrella, D., Napolitano, F., Rispoli, R., Miglietta, M., Carissimo, A., Cutillo, L., Sirci, F., Gregoretti, F., & Di Bernardo, D. (2014). Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis. Bioinformatics (Oxford, England), 30(12), 1787-8. https://doi.org/10.1093/bioinformatics/btu058
Carrella, Diego, et al. "Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis." Bioinformatics (Oxford, England) vol. 30,12 (2014): 1787-8. doi: https://doi.org/10.1093/bioinformatics/btu058
Carrella D, Napolitano F, Rispoli R, Miglietta M, Carissimo A, Cutillo L, Sirci F, Gregoretti F, Di Bernardo D. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis. Bioinformatics. 2014 Jun 15;30(12):1787-8. doi: 10.1093/bioinformatics/btu058. Epub 2014 Feb 20. PMID: 24558125.
Copy Download .nbib Format: NLM
Buying time: Drug repurposing to treat the host in COVID-19H.

Pharmacology research & perspectives

Martin JH, Clark J, Head R.
PMID: 32578336
Pharmacol Res Perspect. 2020 Aug;8(4):e00620. doi: 10.1002/prp2.620.

In 2016 Fedson stated …. "For almost two decades, leading scientists and health officials have warned that we must prepare for a potentially devastating global pandemic of an infectious disease. Initial concern was focused on …H5N1…. More recently…a devastating...

Cite
Martin JH, Clark J, Head R. Buying time: Drug repurposing to treat the host in COVID-19H. Pharmacol Res Perspect. 2020;8(4):e00620doi: 10.1002/prp2.620.
Martin, J. H., Clark, J., & Head, R. (2020). Buying time: Drug repurposing to treat the host in COVID-19H. Pharmacology research & perspectives, 8(4), e00620. https://doi.org/10.1002/prp2.620
Martin, Jennifer H, et al. "Buying time: Drug repurposing to treat the host in COVID-19H." Pharmacology research & perspectives vol. 8,4 (2020): e00620. doi: https://doi.org/10.1002/prp2.620
Martin JH, Clark J, Head R. Buying time: Drug repurposing to treat the host in COVID-19H. Pharmacol Res Perspect. 2020 Aug;8(4):e00620. doi: 10.1002/prp2.620. PMID: 32578336; PMCID: PMC7311221.
Copy Download .nbib Format: NLM
Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research.

Current medicinal chemistry

Vanhaelen Q.
PMID: 32003659
Curr Med Chem. 2021;28(1):181-195. doi: 10.2174/0929867327666200128111925.

Computational approaches have been proven to be complementary tools of interest in identifying potential candidates for drug repurposing. However, although the methods developed so far offer interesting opportunities and could contribute to solving issues faced by the pharmaceutical sector,...

Cite
Vanhaelen Q. Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research. Curr Med Chem. 2021;28(1):181-195doi: 10.2174/0929867327666200128111925.
Vanhaelen, Q. (2021). Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research. Current medicinal chemistry, 28(1), 181-195. https://doi.org/10.2174/0929867327666200128111925
Vanhaelen, Quentin. "Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research." Current medicinal chemistry vol. 28,1 (2021): 181-195. doi: https://doi.org/10.2174/0929867327666200128111925
Vanhaelen Q. Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research. Curr Med Chem. 2021;28(1):181-195. doi: 10.2174/0929867327666200128111925. PMID: 32003659.
Copy Download .nbib Format: NLM
Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning.

BMC bioinformatics

Wang R, Li S, Cheng L, Wong MH, Leung KS.
PMID: 31839008
BMC Bioinformatics. 2019 Dec 16;20:628. doi: 10.1186/s12859-019-3283-6.

BACKGROUND: Development of new drugs is a time-consuming and costly process, and the cost is still increasing in recent years. However, the number of drugs approved by FDA every year per dollar spent on development is declining. Drug repositioning,...

Cite
Wang R, Li S, Cheng L, et al. Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning. BMC Bioinformatics. 2019;20:628doi: 10.1186/s12859-019-3283-6.
Wang, R., Li, S., Cheng, L., Wong, M. H., & Leung, K. S. (2019). Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning. BMC bioinformatics, 20628. https://doi.org/10.1186/s12859-019-3283-6
Wang, Ran, et al. "Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning." BMC bioinformatics vol. 20 (2019): 628. doi: https://doi.org/10.1186/s12859-019-3283-6
Wang R, Li S, Cheng L, Wong MH, Leung KS. Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning. BMC Bioinformatics. 2019 Dec 16;20:628. doi: 10.1186/s12859-019-3283-6. PMID: 31839008; PMCID: PMC6912989.
Copy Download .nbib Format: NLM
Drug databases and their contributions to drug repurposing.

Genomics

Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A.
PMID: 31226485
Genomics. 2020 Mar;112(2):1087-1095. doi: 10.1016/j.ygeno.2019.06.021. Epub 2019 Jun 18.

Drug repurposing is an interesting field in the drug discovery scope because of reducing time and cost. It is also considered as an appropriate method for finding medications for orphan and rare diseases. Hence, many researchers have proposed novel...

Cite
Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, et al. Drug databases and their contributions to drug repurposing. Genomics. 2019;112(2):1087-1095doi: 10.1016/j.ygeno.2019.06.021.
Masoudi-Sobhanzadeh, Y., Omidi, Y., Amanlou, M., & Masoudi-Nejad, A. (2020). Drug databases and their contributions to drug repurposing. Genomics, 112(2), 1087-1095. https://doi.org/10.1016/j.ygeno.2019.06.021
Masoudi-Sobhanzadeh, Yosef, et al. "Drug databases and their contributions to drug repurposing." Genomics vol. 112,2 (2020): 1087-1095. doi: https://doi.org/10.1016/j.ygeno.2019.06.021
Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A. Drug databases and their contributions to drug repurposing. Genomics. 2020 Mar;112(2):1087-1095. doi: 10.1016/j.ygeno.2019.06.021. Epub 2019 Jun 18. PMID: 31226485.
Copy Download .nbib Format: NLM
Link prediction in drug-target interactions network using similarity indices.

BMC bioinformatics

Lu Y, Guo Y, Korhonen A.
PMID: 28095781
BMC Bioinformatics. 2017 Jan 17;18(1):39. doi: 10.1186/s12859-017-1460-z.

BACKGROUND: In silico drug-target interaction (DTI) prediction plays an integral role in drug repositioning: the discovery of new uses for existing drugs. One popular method of drug repositioning is network-based DTI prediction, which uses complex network theory to predict...

Cite
Lu Y, Guo Y, Korhonen A. Link prediction in drug-target interactions network using similarity indices. BMC Bioinformatics. 2017;18(1):39doi: 10.1186/s12859-017-1460-z.
Lu, Y., Guo, Y., & Korhonen, A. (2017). Link prediction in drug-target interactions network using similarity indices. BMC bioinformatics, 18(1), 39. https://doi.org/10.1186/s12859-017-1460-z
Lu, Yiding, et al. "Link prediction in drug-target interactions network using similarity indices." BMC bioinformatics vol. 18,1 (2017): 39. doi: https://doi.org/10.1186/s12859-017-1460-z
Lu Y, Guo Y, Korhonen A. Link prediction in drug-target interactions network using similarity indices. BMC Bioinformatics. 2017 Jan 17;18(1):39. doi: 10.1186/s12859-017-1460-z. PMID: 28095781; PMCID: PMC5240398.
Copy Download .nbib Format: NLM
REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing

Guney E.
PMID: 27896969
Pac Symp Biocomput. 2017;22:132-143. doi: 10.1142/9789813207813_0014.

Repurposing existing drugs for new uses has attracted considerable attention over the past years. To identify potential candidates that could be repositioned for a new indication, many studies make use of chemical, target, and side effect similarity between drugs...

Cite
Guney E. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE. Pac Symp Biocomput. 2017;22:132-143doi: 10.1142/9789813207813_0014.
Guney, E. (2017). REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 22132-143. https://doi.org/10.1142/9789813207813_0014
Guney, Emre. "REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE." Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing vol. 22 (2017): 132-143. doi: https://doi.org/10.1142/9789813207813_0014
Guney E. REPRODUCIBLE DRUG REPURPOSING: WHEN SIMILARITY DOES NOT SUFFICE. Pac Symp Biocomput. 2017;22:132-143. doi: 10.1142/9789813207813_0014. PMID: 27896969.
Copy Download .nbib Format: NLM
Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies.

Current molecular medicine

Jain P, Jain SK, Jain M.
PMID: 32560606
Curr Mol Med. 2021;21(2):111-132. doi: 10.2174/1566524020666200619125404.

BACKGROUND: Traditional drug discovery is time consuming, costly, and risky process. Owing to the large investment, excessive attrition, and declined output, drug repurposing has become a blooming approach for the identification and development of new therapeutics. The method has...

Cite
Jain P, Jain SK, Jain M. Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. Curr Mol Med. 2021;21(2):111-132doi: 10.2174/1566524020666200619125404.
Jain, P., Jain, S. K., & Jain, M. (2021). Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. Current molecular medicine, 21(2), 111-132. https://doi.org/10.2174/1566524020666200619125404
Jain, Priti, et al. "Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies." Current molecular medicine vol. 21,2 (2021): 111-132. doi: https://doi.org/10.2174/1566524020666200619125404
Jain P, Jain SK, Jain M. Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. Curr Mol Med. 2021;21(2):111-132. doi: 10.2174/1566524020666200619125404. PMID: 32560606.
Copy Download .nbib Format: NLM
Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?.

International journal of molecular sciences

Won JH, Lee H.
PMID: 34064287
Int J Mol Sci. 2021 May 21;22(11). doi: 10.3390/ijms22115457.

Therapeutics and vaccines against the COVID-19 pandemic need to be developed rapidly and efficiently, given its severity. To maximize the efficiency and productivity of drug development, the world has adopted disruptive technologies and approaches in various drug development areas....

Cite
Won JH, Lee H. Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?. Int J Mol Sci. 2021;22(11)doi: 10.3390/ijms22115457.
Won, J. H., & Lee, H. (2021). Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?. International journal of molecular sciences, 22(11), . https://doi.org/10.3390/ijms22115457
Won, Jung-Hyun, and Lee, Howard. "Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?." International journal of molecular sciences vol. 22,11 (2021). doi: https://doi.org/10.3390/ijms22115457
Won JH, Lee H. Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?. Int J Mol Sci. 2021 May 21;22(11). doi: 10.3390/ijms22115457. PMID: 34064287; PMCID: PMC8196831.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 29 entries